Male Hypogonadism – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Male Hypogonadism – Pipeline Review, H2 2019’, provides an overview of the Male Hypogonadism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Male Hypogonadism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Male Hypogonadism

– The report reviews pipeline therapeutics for Male Hypogonadism by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Male Hypogonadism therapeutics and enlists all their major and minor projects

– The report assesses Male Hypogonadism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Male Hypogonadism

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Male Hypogonadism

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Male Hypogonadism pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allergan Plc

Diurnal Group Plc

EndoCeutics Inc

Ferring International Center SA

Lipocine Inc

M et P Pharma AG

Medlab Clinical Ltd

Merck & Co Inc

Mereo Biopharma Group Plc

TesoRx Pharma LLC

Viramal Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Male Hypogonadism ”“ Overview

Male Hypogonadism ”“ Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Male Hypogonadism ”“ Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Male Hypogonadism ”“ Companies Involved in Therapeutics Development

Allergan Plc

Diurnal Group Plc

EndoCeutics Inc

Ferring International Center SA

Lipocine Inc

M et P Pharma AG

Medlab Clinical Ltd

Merck & Co Inc

Mereo Biopharma Group Plc

TesoRx Pharma LLC

Viramal Ltd

Male Hypogonadism ”“ Drug Profiles

chorionic gonadotropin ER ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corifollitropin alfa ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

enclomiphene citrate ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IAS-167A ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kisspeptin-10 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leflutrozole ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leuprolide acetate ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Libidua ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LPCN-1111 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Block VDAC1 for Hypogonadism ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rifene ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone propionate ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VERU-722 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Male Hypogonadism ”“ Dormant Projects

Male Hypogonadism ”“ Discontinued Products

Male Hypogonadism ”“ Product Development Milestones

Featured News & Press Releases

Nov 01, 2019: Acerus provides update on temporary unavailability of NATESTO in Canada and South Korea

Oct 23, 2019: Acerus Pharma hosting key opinion leader meeting on unique clinical evidence of NATESTO for treatment of Hypogonadism

Oct 17, 2019: New data demonstrates that Natesto increases serum testosterone and improves symptoms while maintaining normal semen parameters in men with low testosterone through six months

Oct 16, 2019: Aytu BioScience to announce results from Natesto spermatogenesis study on Thursday, October 17

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Male Hypogonadism, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Male Hypogonadism ”“ Pipeline by Allergan Plc, H2 2019

Male Hypogonadism ”“ Pipeline by Diurnal Group Plc, H2 2019

Male Hypogonadism ”“ Pipeline by EndoCeutics Inc, H2 2019

Male Hypogonadism ”“ Pipeline by Ferring International Center SA, H2 2019

Male Hypogonadism ”“ Pipeline by Lipocine Inc, H2 2019

Male Hypogonadism ”“ Pipeline by M et P Pharma AG, H2 2019

Male Hypogonadism ”“ Pipeline by Medlab Clinical Ltd, H2 2019

Male Hypogonadism ”“ Pipeline by Merck & Co Inc, H2 2019

Male Hypogonadism ”“ Pipeline by Mereo Biopharma Group Plc, H2 2019

Male Hypogonadism ”“ Pipeline by TesoRx Pharma LLC, H2 2019

Male Hypogonadism ”“ Pipeline by Viramal Ltd, H2 2019

Male Hypogonadism ”“ Dormant Projects, H2 2019

Male Hypogonadism ”“ Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development for Male Hypogonadism, H2 2019 9

Number of Products under Development by Companies, H2 2019 10

Number of Products by Targets, H2 2019 16

Number of Products by Stage and Targets, H2 2019 16

Number of Products by Mechanism of Actions, H2 2019 18

Number of Products by Stage and Mechanism of Actions, H2 2019 18

Number of Products by Routes of Administration, H2 2019 20

Number of Products by Stage and Routes of Administration, H2 2019 20

Number of Products by Molecule Types, H2 2019 22

Number of Products by Stage and Molecule Types, H2 2019 22

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports